Last updated on April 23, 2014 at 21:24 EDT

Introducing CerAxon®, the First & Only Oral Solution Medical Food for Dietary Management of Brain Ischemia in Patients With Partially Impaired Swallowing

October 13, 2011

MOUNTAIN LAKES, N.J., Oct. 13, 2011 /PRNewswire/ — Ferrer Therapeutics, the U.S. subsidiary of international pharmaceutical group, Ferrer Grupo, is introducing CerAxon® Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline. Taken for the dietary management of brain ischemia due to stroke or traumatic brain injury (TBI), CerAxon® Oral Solution provides patients who have difficulty swallowing with elevated citicoline required to help stabilize the brain, specifically during the first six weeks following injury.

(Logo: http://photos.prnewswire.com/prnh/20111013/NY85320LOGO )

Citicoline is found in every cell in the body and is one of the most intensely investigated naturally occurring chemicals found in the human brain. After injury from stroke or TBI, the brain’s demand for citicoline may increase as it tries to save damaged cells. Dr. David Chiu, Associate Professor, Cornell University and Director, Stroke Neurology at Methodist Hospital, Houston, explains that, “Just a 10% loss of citicoline in the body is sufficient enough to alter brain cell membrane function and induce neuron cell death. The first six weeks after injury are when the brain’s partially damaged cells need assistance to begin the recovery and reprogramming process.”

Studies show citicoline has a tolerability profile similar to placebo(1), with no significant systemic cholinergic effects, and no serious side effects.

Dr. Claudia Penalba, Board Certified Physical Rehabilitation Specialist and Founder of Penalba Physical Rehabilitation in Miami, has been using CerAxon with her stroke patients and explains, “CerAxon Oral Solution helps improve stroke and brain injury recovery and return the body to normal daily movement activities, such as eating, bathing and walking, as well as improving temporal and spatial orientation, learning, memory and ability to focus.”

No serious adverse reactions for individuals taking CerAxon Oral Solution have been reported. CerAxon Oral Solution should be taken for the first six weeks after injury.

CerAxon Oral Solution is a medical food and is to be used under the supervision of a physician. It is available without a prescription by request at local pharmacies or through www.ceraxon.com.

(1) Davalos A, et al. Oral citicoline in acute ischemic stroke: An individual patient data pooling analysis of clinical trials. Stroke 2002;33:2850-2857.

SOURCE Ferrer Therapeutics

Source: PR Newswire